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Abstract: Refeeding syndrome (RFS) is the metabolic response to the switch from starvation to
a fed state in the initial phase of nutritional therapy in patients who are severely malnourished
or metabolically stressed due to severe illness. It is characterized by increased serum glucose,
electrolyte disturbances (particularly hypophosphatemia, hypokalemia, and hypomagnesemia),
vitamin depletion (especially vitamin B1 thiamine), fluid imbalance, and salt retention, with resulting
impaired organ function and cardiac arrhythmias. The awareness of the medical and nursing staff is
often too low in clinical practice, leading to under-diagnosis of this complication, which often has
an unspecific clinical presentation. This review provides important insights into the RFS, practical
recommendations for the management of RFS in the medical inpatient population (excluding eating
disorders) based on consensus opinion and on current evidence from clinical studies, including risk
stratification, prevention, diagnosis, and management and monitoring of nutritional and fluid therapy.
Keywords: refeeding syndrome; diagnosis; management; malnutrition; hypophosphatemia;
nutritional support; nutritional therapy
1. Introduction
During World War II, many people suffered from hunger and starvation. Under these
circumstances, Ancel Keys investigated the physical and mental effects of prolonged dietary restriction
and the subsequent refeeding of 36 conscientious objectors in the Minnesota Starvation Experiment [1].
Most of the subjects experienced periods of severe emotional distress, depression, social withdrawal,
isolation, decline in concentration, and decreases in metabolic rate, respiration, and heart rate. Several
of the participants developed edema in their extremities. Later, at the end of World War II, further
observations were made by Schnitker and Burger [2,3]. Numerous starving detainees developed severe
symptoms such as heart failure, peripheral edema, and neurological disorders after a normal diet was
reintroduced, and one of five died within the next few days [2,3]. Those observations led to the first
description of the refeeding syndrome (RFS), almost 75 years ago.
To date, there is still no commonly accepted definition of RFS, and its detailed pathophysiology
remains largely unclear. This is primarily due to the fact that the clinical manifestations of RFS are
nonspecific, leading to RFS frequently being overlooked, underdiagnosed, and subsequently untreated.
In the study of Hernandez-Aranda et al., up to 48% of malnourished inpatients developed RFS [4].
A sub-analysis of the just-published study of Schuetz et al. demonstrates that medical patients with
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confirmed RFS have significant mortality rates and increased non-elective hospital readmission, thus
confirming the negative effect of RFS on clinical outcome [5,6].
Nutritional treatment is a central aspect of modern multimodal inpatient therapy. It aims to
reduce complications and mortality rates, and to improve patients’ quality of life and autonomy [5,7].
Even though well tolerated, nutritional treatment has a potential risk of complications, including
RFS, which is an exacerbated response to the metabolic change from a starvation to a fed state as a
consequence of large amount of food in the replenishment phase. RFS is characterized by an imbalance
of electrolytes (mainly phosphate, potassium, and magnesium), vitamin disturbances (e.g., vitamin B1
thiamine deficiency), and fluid imbalances, as well as limited organ functions, in some cases leading to
mortality [8–12]. This article highlights, discusses, and reviews RFS in medical inpatients (excluding
patients with eating disorders) in terms of pathophysiological aspects, preventive measures, clinical
manifestations, risk evaluation, diagnostic procedures, and treatment methods.
2. Pathophysiology and Clinical Manifestations
RFS is an exaggerated physiological response to glucose reintroduction (refeeding) after a
prolonged phase of starvation or scarce food intake [13]. The precise pathophysiological mechanisms
remain unclear, but recent assumptions are based on the processes described below (Figure 1).
In a catabolic state (due to reduced food intake or even starvation), insulin production is decreased,
whereas glucagon and catecholamine are slightly stimulated [14]. During a fasting period, glucose
oxidation is reduced and only takes place in the glucose-dependent tissues, such as the brain, renal
medulla and red blood cells. The glycogen stores are reduced, leading to activation of gluconeogenesis
and the production of glucose from endogenous amino acids, which are released by increased
proteolysis. This process causes a reduction in muscle mass, thus inducing functional weakness and
weight loss. Vitamin and electrolyte levels are decreased and stores are depleted [15]. After a few
days, lipolysis increases, subsequently leading to raised levels of free fatty acids in the circulation.
These free fatty acids stimulate ketogenesis in the liver, leading to high production of ketone bodies
(in particular acetoacetate and beta-hydroxybuturate), which become the main suppliers of energy
for the body [16]. During the catabolic state, metabolic processes are reduced to 30–50% of normal
(adaptation phase) [13].
If balanced nutritional support with carbohydrates (refeeding) is introduced, glucose becomes
the main energy supplier again, causing hyperglycemia and consequently an increase in insulin
secretion. Anabolic processes are stimulated, leading to intracellular shifts of glucose, water, and
electrolytes, and resulting in a potentially severe drop in serum micronutrient levels. The resulting
electrolyte imbalances can cause life-threatening complications such as arrhythmia, spasms, or
tetany [8,11,15,17,18]. Acid-base balance can cause significant electrolyte shifts and this needs to
be considered as a differential diagnosis/contributing cause when suspecting refeeding syndrome
(e.g., respiratory acidosis). A significant drop in phosphate, potassium, or magnesium levels may
occur when the patient has been acidotic, and this is starting to resolve. As the intracellular shift of
glucose is thiamine dependent, a deficiency in thiamine, as observed during catabolism, can lead to
symptoms of beriberi. The more compromised the nutritional state, the higher the risk of RFS and the
greater the severity of its manifestations [8,12]. There are many non-specific symptoms that potentially
occur during RFS; the most commonly observed clinical symptoms in daily practice are tachycardia,
tachypnea, and peripheral edema [8,15,19,20].
Clinical consequences due to electrolyte changes following increases in insulin include:
– Phosphate is an important electrolyte in the metabolism of macronutrients for both the energy
production and transport processes. Phosphate is especially important in the refeeding phase, since
glycolysis requires only phosphorylated glucose. Hypophosphatemia may cause several clinical
manifestations, such as rhabdomyolysis, hemolysis, respiratory failure, and musculoskeletal
disorders. Severe hypophosphatemia (<0.32 mmol/L) is considered a typical hallmark of RFS and
in several studies is a central defining criterion [15,18].
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– Potassium and magnesium are also important intercellular cations. Severe hypokalemia
(<2.5 mmol/L) and/or hypomagnesemia (<0.50 mmol/L) may trigger potentially lethal arrhythmia,
neuromuscular dysfunctions such as paresis, rhabdomyolysis, confusion, and respiratory
insufficiency [15].
– Thiamine is an essential coenzyme in the metabolism of carbohydrates, allowing the conversion
from glucose to adenosine triphosphate (ATP) via the Krebs cycle. When thiamine is lacking
(human body stores last for approximately 14 days), glucose is converted to lactate, leading to
metabolic acidosis. Thiamine deficiency may also lead to neurologic (Wernicke’s encephalopathy:
dry beriberi) or cardiovascular disorders (wet beriberi) [15,16].
– Sodium: The major influence on the serum sodium level during the refeeding phase is the shift of
sodium out of the cell as the potassium is pumped back into the cell (sodium-potassium-ATPase
pump). In addition, the increased insulin level in the early phase of refeeding leads to sodium
retention in the kidneys. Sodium concentration subsequently increases, thus inducing water
retention. Noradrenaline and angiotensin II are stimulated and lead to augmented peripheral
resistance and vasoconstriction [21]. This may cause peripheral edema and heart failure.
Figure 1. Pathophysiology of refeeding syndrome [22]. Used by permission of the Division of Diabetes,
Endocrinology, Nutritional Medicine and Metabolism, Prof. Dr. med. Zeno Stanga (2019).
3. Current Level of Evidence
The current state of evidence for RFS was recently summarized in a systematic review by Friedli
et al. [20]. It is mainly based on case series and retrospective, cohort, and case-control studies. To date,
very few randomized controlled trials have been published. A recent experts’ consensus defined risk
factors, occurrence, incidence rate, preventive measures, and treatment recommendations in medical
inpatients [19]. A literature search for newly published studies was performed according to the criteria
of Friedli et al. for the systematic literature review, excluding anorexia nervosa [20]. Due to the
scarce evidence, the National Institute for Health and Care Excellence (NICE) guidelines on nutritional
support in adults, containing recommendations on identification and treatment of malnutrition as well
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as management of nutritional therapy, are often used as the standard of care [23]. Consistent data on
the management of RFS and adverse clinical outcome are largely lacking, and justify further research
on specific preventive, screening, and treatment measures in patients at risk.
A secondary analysis of a large randomized controlled trial (EFFORT trial [5]) showing the
beneficial effects of nutritional support in hospitalized patients provides evidence that, due to the
consequences of RFS (higher mortality and non-elective readmission rates), patients at risk may benefit
from a specific treatment [5,6]. This secondary analysis relying on the risk stratification and definition
from the above-mentioned experts’ consensus [19] largely confirms the proposed risk factors and
occurrence of RFS [6,8,12,19].
4. Prevention
4.1. Nutritional Support Teams
RFS is most likely to occur within the first 72 h after the start of nutritional therapy (replenishment
phase), and to progress rapidly [20]. Quick recognition is crucial and requires well-trained medical
staff [24]. In most hospitals, multidisciplinary nutritional support teams are available and assist the
attending medical staff in the management of malnutrition. Such teams—consisting of physicians,
dieticians, nurses, and pharmacists—contribute to improved quality and safety and optimal clinical
outcomes [25–27].
4.2. Individual Risk Assessment
Although RFS is associated with severe and potentially lethal complications, it is a preventable
condition [4,28,29]. It can occur with any kind of nutritional intervention (oral, enteral, or parenteral) [28].
RFS risk predictors have been investigated in many studies, but sensitivity and specificity are low [29–31].
Starvation remains the most reliable predictor of RFS [28]. Nutritional risk screening 2002 ≥ 3 points,
polymorbidity, older age, and low serum magnesium (<0.7 mmol/L) were found to be risk factors
for RFS in many studies [19,20,28,32–38]. According to the literature and to our long-lasting daily
clinical experience, there are many clinical conditions at particular risk of developing RFS (see
Table 1). Oncological and geriatric patients are very likely to develop RFS [4,39]. Underlying diseases
and conditions affecting nutrient absorption (e.g., short bowel syndrome, bariatric surgery, eating
disorders) may be risk factors as well [35]. Moreover, chronic gastrointestinal symptoms (e.g., diarrhea,
vomiting) and polypharmacy may increase the risk of RFS [19,20,40]. Additionally, medical therapeutic
interventions like hemodialysis or chemotherapy are associated with a high risk of RFS [14,23,26].
Before starting nutritional therapy, it is therefore recommended by the experts’ consensus of Friedli
et al. (Figure 2) to assess the patient’s individual risk of RFS and to adapt the nutritional care plan
accordingly [19,20,23].
Table 1. Clinical conditions at particular risk of developing RFS.
Clinical Conditions
- Malnourished, catabolic patients
- Geriatric patients
- Oncologic patients
- Trauma patients
- Critically ill patients
- Hunger strikers or prolonged fasting
- Short -bowel syndrome
- Bariatric surgery
- Anorexia nervosa
- Cystic fibrosis
- Chronic wasting disease
- Chronic pancreatitis
- Chronic infectious disease
- Inflammatory bowel syndrome
- Liver cirrhosis
- Patients with dysphagia
- Patients with hemodialysis
- Patients with chemotherapy
- Patients with chronic alcoholism
- Drug dependent patients
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Figure 2. Risk stratification for RFS, according to [19,23]. This stratification has not been validated in a
clinical trial [22]. Used by permission of the Division of Diabetes, Endocrinology, Nutritional Medicine
and Metabolism, Prof. Dr. med. Zeno Stanga (2019).
5. Diagnostic Procedure
Even though RFS was identified more than 75 years ago, no common definition exists.
Therefore, the diagnosis is often delayed or can even be overlooked. Electrolyte imbalance, mainly
hypophosphatemia, was used to define RFS in several studies [8,15,41]. Clinical manifestations such as
edemas, respiratory failure, or heart failure may occur as a consequence of the electrolyte imbalances,
vitamin deficiencies, and fluid overload. The diagnostic procedure proposed by Friedli et al. consists
of pathophysiological and clinical characteristics (Figure 3). RFS is probable if the phosphate level
in the blood drops >30% under the lower normal value or under 0.6 mmol/L, or if two of the three
electrolytes (phosphate, magnesium, and potassium) drop under the normal values within the first
72 h after the start of the replenishment phase in the absence of other possible causes [19,20]. RFS
manifests as soon as clinical symptoms occur in addition to electrolyte imbalance [19,20].
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Figure 3. Diagnosis of RFS according to [19], and adapted from Rio et al. [28]. These diagnostic
criteria have not been validated in a clinical trial [22]. Used by permission of the Division of Diabetes,
Endocrinology, Nutritional Medicine and Metabolism, Prof. Dr. med. Zeno Stanga (2019).
6. Clinical Management
Each malnourished, catabolic patient should receive the best nutritional support according to the
highest quality standards in a timely fashion. A recent randomized controlled trial demonstrated the
efficacy of adequate nutritional management [5]. Patients at risk of developing RFS need replenishment
of electrolytes and vitamins (especially thiamine) serum levels to help prevent/treat symptoms. In this
study, the data from 967 malnourished patients were analyzed for RFS; 141 (14.6%) had confirmed RFS,
indicating the high incidence of this metabolic state in medical patients receiving nutritional support [6].
The clinical manifestation can vary from mild forms with limited clinical signs and symptoms to severe
forms with potentially lethal complications.
Diverse trials evaluated preventive approaches for RFS, such as substitution of electrolytes,
thiamine administration, and hypocaloric feeding. Most studies used for the proposed nutritional
management were observational and not interventional, pointing to the overall low level of evidence
(see Table 2 for guidelines and Table 3 for trials). From the 45 studies included in the systematic
review of Friedli et al. [20], only a few reported on therapeutic strategies to treat RFS; some of them
reported phosphate supplementation to be effective. Several studies demonstrated a preventive
effect of hypocaloric feeding and a reduced risk of RFS when replacing electrolytes. Moreover, close
monitoring of serum electrolytes is a further measure for the reduction of risk of RFS.
Based on a previously published systematic review, international experts in the field of starvation
metabolism and refeeding published a consensus paper [20]. There was a moderate agreement
concerning the initial treatment of high-risk patients and prophylactic measures to prevent RFS. For
the proposed treatment of imminent or manifest RFS, there was a strong agreement. In this regard, it is
advantageous to manage nutritional and fluid intake as proposed in Figure 4.
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Table 2. Relevant guidelines and reviews regarding the management of RFS.
Reference Type of Study Level ofEvidence Initial Energy/day Proteins/day Fluids/day Vitamins (Before/During)
Solomon et al. 1990 [11] Review 4 20 kcal/kg 1.2–1.5 g NR NR
Dewar et al. 2000 [42] Review, guidelines 4 20 kcal/kg NR NR Thiamine IV or PO for 2 days
Crook et al. 2001
[8] Review 4
10 kcal/kg
high risk: 5 kcal/kg
50–60% CHO, 15–25% fat
20–30%
1.2–1.5 g
20–30 mL/kg,
0 fluid balance
Thiamine 300 mg IV, than 100 mg
daily during refeeding. In addition,
Vit B12, Vit B6 and folate
Stroud et al. 2003 [43] Review 4 10–20 kcal/kg NR NR Thiamine and B vitamins IV for 3 days
Kraft et al. 2005
[44] Review, guidelines 4 7.5 kcal/kg NR <1000 mL/day
Thiamine 50–100 mg IV or 100 mg PO
for 5–7 days and multivitamin
NICE 2006
[23] Review, guidelines 4
10 kcal/kg
high risk: 5 kcal/kg NR 0 fluid balance
Thiamine 200–300 mg PO for 10 days
and multivitamin for 10 days
Stanga et al. 2008 [12] Case series 4
10–15 kcal/kg
high risk: 5 kcal/kg
50–60% CHO, 30–40% fat
15–20% 20–30 mL/kg,0 fluid balance
Thiamine 200–300 mg IV or PO for 3
days and multivitamin for 10 days
Mehanna et al. 2008 [16] Review 4 10 kcal/kghigh risk: 5 kcal/kg NR
carefully fluid
repletion
Thiamine 200–300 mg PO for 10 days
and multivitamin for 10 days
Boateng et al. 2010 [15] Case series 4
10 kcal/kg
high risk: 5 kcal/kg
50–60% CHO, 15–25% fat
20–30%
1.2–1.5 g
20–30 mL/kg,
0 fluid balance
Thiamine 300 mg IV, then 100 mg
daily during refeeding. In addition,
Vit B12, Vit B6 and folate
ESPEN 2019
[45] Review, guidelines 4
10–15 kcal/kg
high risk: 5 kcal/kg
50–60% CHO, 30–40% fat
15–20% 20–30 mL/kg,0 fluid balance
Thiamine 200–300 mg IV or PO for 3
days and multivitamin for 10 days
Crook et al. 2014 [46] Review 4
10 kcal/kg
high risk: 5 kcal/kg
50–60% CHO, 15–25% fat
20–30%
1.2–1.5 g
20–30 mL/kg,
0 fluid balance
Thiamine 300 mg IV, then 100 mg
daily during refeeding. In addition,
Vit B12, Vit B6 and folate
Friedli et al. 2017 [20] Systematic review 3a
10–15 kcal/kg
high risk: 5 kcal/kg
50–60% CHO, 30–40% fat
15–20% 20–30 mL/kg,0 fluid balance
Thiamine 200–300 mg IV or PO for 3
days and multivitamin for 10 days
Friedli et al. 2018 [19] Systematic review, consensuspaper 3a
10–15 kcal/kg
high risk: 5 kcal/kg
50–60% CHO, 30–40% fat
15–20% 20–30 mL/kg,0 fluid balance
Thiamine 200–300 mg IV or PO for 3
days and multivitamin for 10 days
CHO: carbohydrates, IV: intravenous, NR: not reported, PO: per os. Level of evidence after level of evidence for clinical studies from the Oxford centre for evidence-based medicine,
http://www.cebm.net; 4 case series (and poor-quality cohort and case-control studies); 3a systematic review (with homogeneity) of case-control studies; 3b individual case-control study.
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Table 3. Relevant studies regarding the management of RFS.
Reference Type of Study Level ofEvidence N Preventive Medication Therapeutic Medication Effectivity
Hofer et al. 2014 [25] Retrospective study 3b 86
Hypocaloric feeding, restricted fluid administration (0 fluid
balance), thiamine 200–300 mg IV or PO for 3 days and
multivitamin for 10 days, electrolyte supplementation
(unless prefeeding serum levels are high): PO4 0.5–0.8
mmol/kg/day, K 1–2.2 mmol/kg/day, Mg 0.3–0.4
mmol/kg/day
Hypocaloric feeding, restricted fluid
administration, electrolytes
substitution according to the serum
level
Yes
Eichelberger et al. 2014 [47] Retrospective study 3b 37
Hypocaloric feeding, restricted fluid administration (0 fluid
balance), thiamine 200–300 mg IV or PO for 3 days and
multivitamin for 10 days, electrolyte supplementation
(unless prefeeding serum levels are high): PO4 0.5–0.8
mmol/kg/day, K 1–2.2 mmol/kg/day, Mg 0.3–0.4
mmol/kg/day
Hypocaloric feeding, restricted fluid
administration, electrolytes
substitution according to the serum
level
Yes
Terlevich et al. 2003 [31] Prospective study 4 30 NR 50 mmol PO4 over 24h Yes
Gonzalez Aviva et al. 1996
[48] Prospective study 3b 106 PO4 supplementation NR Yes
Marvin et al. 2008 [49] Case control study 3b 140 During the first 24 h slow PN regimen providing <70% ofprotein and calories but >12 mmol PO4
NR Yes
Garber et al. 2011 [50] Retrospective study 4 40 No effective preventive measures found NR No
Coskun et al. 2014 [51] Retrospective study 4 117 Lower energy intake NR No
Doig et al. 2015 [52] RCT 1b 339 NR Lower caloric intake Yes
Whitelaw et al. 2010 [53] Retrospective study 4 46 Prophylactic administration of PO4, lower initial energyintake, monitoring of PO4
Supplementation of PO4 Yes
Luque et al. 2007 [54] Retrospective study 4 11 PO4 supplementation, thiamine 3.51 mg/d NR Yes
Manning et al. 2014 [55] Prospective study 2b 36 Repeated electrolyte testing NR No
Fan et al. 2004 [33] Retrospective study 4 158 PO4 supplementation NR Yes, if PO4 <0.30
Gentile et al. 2010 [56] Retrospective study 4 33 Prophylactic administration of PO4 and K, cautiousnutritional rehabilitation NR Yes
Vignaud et al. 2010 [38] Retrospective study 4 68 For patients at risk for initial nutritional support 10kcal/kg/day falling to as low as 5 kcal/kg/day NR Yes
Chen et al. 2014 [57] Retrospective study 4 56 Thiamine and multivitamin supplementation, 15kcal/kg/day NR Yes
Golden et al. 2013 [58] Retrospective study 4 310 Lower caloric intake NR No
Leclerc et al. 2013 [59] Retrospective study 4 29 Hypocaloric feeding NR No
Flesher et al. 2005 [60] Retrospective study 4 51 Thiamine supplementation, cautious feeding NR No
Rio et al. 2013 [28] Prospective 2b 243 Hypocaloric feeding NR No
IV: intravenous, NR: not reported, PO: per os, RCT: randomized controlled trial. Level of evidence after Level of evidence for clinical studies from the Oxford Centre for Evidence-based
Medicine, http://www.cebm.net.
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Figure 4. Management of nutritional therapy according to the risk for RFS, after [19]. Used by
permission of the Division of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, Prof. Dr.
med. Zeno Stanga (2019) [22].
6.1. Macronutrients
Various studies and guidelines have shown a beneficial effect of starting energy intake at a lower
rate than generally used, in order to prevent RFS in patients at high risk [12,16,23]. Based on a patient’s
individual risk for RFS, energy supply should be initiated at lower levels, starting with an initial
amount of 5–15 kcal/kg/day, and increased stepwise depending on the laboratory parameters and
clinical situation of the patient [8,19,20,23,52,61,62]. The full energy requirements should be met within
5 to 10 days, depending on the prior risk stratification, using a common nutritional macronutrients
composition of 40–60% carbohydrates, 30–40% fats, and 15–20% proteins [12]. In clinically unstable
critically ill patients with RFS, lowering the proportion of carbohydrates should be considered.
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Nutritional rehabilitation of patients with risk to develop a RFS should be typically started with
oral intake of regular food. If the patient cannot eat enough food to meet the energy targets, oral
nutritional supplements may be prescribed. Enteral nutrition (tube feeding) is indicated for extremely
malnourished patients (e.g., very low BMI) or patients who are unable to consume enough food to
reach the energy targets. Parenteral nutrition is indicated when oral and/or enteral nutrition are
insufficient or in the case of failure of the gut function. The risk of RFS may be greater with enteral or
parenteral feeding compared to oral intake, thus artificial nutrition should be started cautiously at a
reduced caloric rate [4,28,29,52,63–66].
Optimal nutritional support is still controversial and some experts and scientists recommend
faster increase in nutritional support to counteract harm associated with malnutrition. Opinions on its
management differ, because they are mostly based on personal experience in various populations. At
this point, we would like to emphasize that the current review provides important insights into RFS
based on a comprehensive literature research and critical appraisal of the evidence. In the light of the
current scientific knowledge, it is very likely that there is a need for different intervention approaches
adapted to the specific pathologies, e.g., anorexia nervosa.
6.2. Fluids
Disturbance of the acid-base balance may cause hypophosphatemia. Acute respiratory alkalosis
is for example the most common clinical situation in which hypophosphatemia should be expected
in hospitalized patients. The often uncritical use of diuretics (loop and thiazide diuretics) promotes
the development of alkalosis through volume reduction and loss of electrolytes (chloride, potassium,
magnesium). A decreased volume generates metabolic alkalosis in two ways. The reduction of
phosphate is much more pronounced in respiratory alkalosis than in metabolic alkalosis of comparable
severity [67,68].
RFS may occur regardless of energy restrictions if fluid balance is disregarded [39]. Hydration
deficiencies and abnormal losses (e.g., fever, vomiting, diarrhea) should be addressed at the start
of a replenishment phase. The choice of replacement fluid is thereby especially relevant. Balanced
solutions should be the preferred option, except when replacing gastric and/or fistula losses over
stoma. The fluid prescription should include the daily maintenance requirements plus the water and
electrolytes replacement of any losses [69]. In general, fluid intake of 25–35 mL/kg/day is sufficient to
maintain an adequate hydration state [69]. The fluid intake through artificial nutrition, infusions, and
intravenously administered drugs (mainly antibiotics) should also be taken into account, as well as the
salt content (up to 155.2 mmol of Na+ in one liter of Ringer’s lactate (Hartmann) solution and 154 mmol
of Na+ in one liter of isotonic 0.9% NaCl solution). Fluid balance should be corrected cautiously and
checked daily. Diuretics, especially specific competitive aldosterone antagonists regulating sodium
transport in the kidney, may be useful in case of fluid excess [69].
Particular attention should be paid to the sodium concentration of fluids/products given to patients
at (very) high risk for RFS. Sodium restriction (<1 mmol/kg/day) should be considered in the first days
after the start of the nutritional therapy in order to avoid fluid overload [12,19,25,47].
6.3. Micronutrients
Malnourished patients have depleted intracellular micronutrient stores. After the initiation of
nutritional therapy, the intracellular flux of vitamins and electrolytes increases, causing serum levels
to drop. It is therefore essential to correct electrolyte levels before initiation of the replenishment
phase, with the supplementation of phosphate and thiamine being particularly important [15,19,20].
Prophylactic phosphate supplementation should be undertaken in patients at very high risk for RFS
even in the case of normal serum levels to avoid or alleviate the occurrence of RFS, as hypophosphatemia
plays a key role in RFS. During starvation, body stores of phosphate decrease, despite normal serum
levels. As long as the energy metabolism depends on fat oxidation, phosphate is not required; as
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soon as the patient resumes carbohydrate intake, the metabolism of glucose uses large amounts of
phosphate, thus leading to a drop in serum levels [12,15,64].
The prophylactic supplementation of high-dose thiamine (200–300 mg) at least 30 min before
beginning refeeding is fundamental. Vitamins should be supplemented to 200% and the trace
elements to 100% of the recommended daily intakes. Electrolytes, especially phosphate, potassium, and
magnesium, must be closely monitored and supplemented throughout the refeeding period [12,19,25,47].
Hypokalemia is worsened by concomitant hypomagnesemia, since magnesium is necessary for the
sodium-potassium-pump activity and therefore an important factor in the tubular resorption of
potassium. Potassium supplementation alone is thus insufficient, and persistently low potassium
values despite supplementation can subsequently be rectified only with simultaneous magnesium
substitution [70]. Hypocalcemia may cause or further worsen hypophosphatemia [71].
Iron should not be supplemented in the first week after the start of the nutritional therapy, even
in the case of manifest iron deficiency. As blood production requires high amounts of potassium,
hypokalemia may worsen further. Moreover, parenteral iron supplementation must be considered with
caution in malnourished catabolic patients, as it may induce and/or prolong hypophosphatemia [7].
7. Monitoring
RFS generally occurs within the first 72 h after initiation of nutritional therapy and may progress
very rapidly. In the vulnerable phase (up to 10 days), intensive clinical monitoring of vital signs and
hydration status, as well as analysis of laboratory parameters, is essential to detect early signs of
RFS such as fluid overload and organ failure (mainly kidney) (Figure 5). Body weight and hydration
status should be checked on a daily basis, as an increase of 0.3–0.5 kg/day may be an initial sign of
pathological fluid retention [12,19,25,47].
Figure 5. Monitoring of RFS, based on [19]. Used by permission of the Division of Diabetes,
Endocrinology, Nutritional Medicine and Metabolism, Prof. Dr. med. Zeno Stanga (2019) [22].
Electrocardiogram monitoring is recommended only during the first three days in patients at very
high risk of RFS or affected by severe electrolyte imbalances prior to refeeding (K < 2.5 mmol/L, PO4 <
0.32 mmol/L, Mg < 0.5 mmol/L), as they may exhibit severe arrhythmia and QT-prolongation, up to
Torsades de Pointes [8,12,19,20,23].
Electrolyte substitution respectively supplementation should be initiated or reinforced in case of
extracellular electrolyte levels dropping (Table 4). In the case of edema, tachycardia, or tachypnea,
symptoms should be treated individually and nutritional therapy should be continued according to
the algorithm for the highest risk category [15,19,20].
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Table 4. Suggested supplementation regimen [8,12,72–76].
Potassium Magnesium Phosphate
Mild deficiency
3.1–3.5 mmol/L
Oral replacement with 20 mmol (as
KCl or other salts)
OR
i.v. replacement with 20 mmol KCl
over 4 to 8 h. Check levels the next
day.
0.5–0.7 mmol/L
Oral replacement with 10–15
mmol MgCl2 or Mg-citrate or
Mg-L-aspartate
Oral Mg should be given in
divided doses to minimize
diarrhea (absorption process is
saturated at about 5–10 mmol Mg)
0.61–0.8 mmol/L
Oral replacement with 0.3
mmol/kg/day PO4 (divided doses to
minimize diarrhea)
OR
i.v. replacement with 0.3
mmol/kg/day PO4 (as K3PO4 or
Na3PO4) over 8–12 h. Check levels
the next day.
Moderate
deficiency
2.5–3.0 mmol/L
i.v. replacement with 20–40 mmol
KCl over 4–8 h. Check levels after 8
h; if not normal, give an additional
20 mmol KCl.
0.32–0.6 mmol/L
i.v. replacement with 0.6
mmol/kg/day PO4 (as K3PO4 or
Na3PO4) over 8–12 h. Check levels
after 8–12 h and repeat infusion if
necessary (max. of 50 mmol PO4 in
24 h).
Severe
deficiency
<2.5 mmol/L
i.v. replacement with 40 mmol KCl
over 4–8 h. Check levels after 8 h; if
not normal, give an additional 40
mmol KCl.
<0.5 mmol/L
i.v. replacement with 20–24 mmol
MgSO4 (4–6 g) over 4–8 h.
Reassess every 8 to 12 h.
<0.32 mmol/L
Same replacement therapy as for
moderate deficiency.
8. Important Clinical Sequelae of Refeeding Syndrome and Management of Complications
RFS may increase rates of morbidity and mortality in severely catabolic patients (Table 5).
Malnutrition may result from reduced food intake, reduced absorption of nutrients (e.g., coeliac
disease, pancreatitis), or hypermetabolism (e.g., cancer, critical illness, surgery). Mild metabolic
imbalances of electrolytes, fluid, and micronutrients are however often asymptomatic but may cause
organ dysfunctions and become potentially lethal. Peripheral edema, tachypnea, and tachycardia are
the most commonly observed clinical symptoms in patients suffering RFS. It is mandatory to treat
these symptoms if they occur, ruling out an eventual lung embolism.
The first step in the management of RFS-related pathological conditions is to anticipate with
preventive measures and closely monitor the at-risk patients. The overall objectives in the treatment
of RFS complications are to stabilize the patient’s general clinical state, to reverse the medical
complications, as well as to restore nutritional needs and weight. The sooner the RFS complications
are treated, the lower the risk of damage to patient’s vital organs. The patients with RFS are often
dehydrated and require correction of existing hydration deficits and replacement of abnormal fluid
losses. Furthermore, electrolytes and vitamins have to be supplemented adequately, as well as any
deficiency corrected. The nutritional rehabilitation should be started slowly and adapted to each
individual patient. The introduction of carbohydrates in the replenishment phase leads to a quick
decrease in renal excretion of sodium and water [21,77]. Patients require a close monitoring of the
fluid balance to prevent fluid overload. Such uncontrolled clinical situations may lead quickly to
congestive cardiac failure, pulmonary and brain edema, as well as cardiac arrhythmia [78,79]. Too
much delivering of glucose in this vulnerable phase leads to hyperglycemia and consequently to
osmotic diuresis, dehydration metabolic acidosis, hyperosmotic coma, and ketoacidosis, as well as
increased carbon dioxide, hypercapnia, and respiratory failure [77,80–82]. Severely malnourished
patients may suffer from hematological disorders and moderate to high increase of liver enzymes. The
first pathophysiological changes are associated with bone marrow hypoplasia and with gelatinous
marrow transformation [83,84]; the second seems to be multicausal and related to an ischemic
hepatitis secondary to liver hypoperfusion, to oxidant stress from low glutathione levels, and to
starvation-induced autophagy [83,85]. Both pathologies show a marked decrease after a few days
during the replenishment phase (hydration and nutritional therapy) and possibly will normalize after
the refeeding period [86]. In all these clinical situations, a complications-centric approach to RFS-related
complications identifies patients who will benefit most from individual specific interventions and
optimizes patient outcomes.
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Table 5. Important symptoms and clinical sequelae of RFS (adapted from [15]).
System Symptoms
Cardiovascular
Tachycardia
Arrhythmias
Hypotension
Congestive heart failure
Shock
Edemas
Sudden death
Gastrointestinal
Maldigestion and malabsorption
Vomiting
Constipation
Abdominal pain
Musculoskeletal
Weakness
Myalgia
Rhabdomyolysis
Osteomalacia
Respiratory
Tachypnea
Dyspnea
Respiratory failure
Ventilator dependency
Diaphragm muscle weakness
Neurologic
Anorexia
Paresthesia
Tremor
Wernicke encephalopathy
Korsakoff syndrome
Ataxia
Tetany
Delirium
Seizures
Coma
Metabolic
Hyperglycemia
Metabolic alkalosis
Metabolic acidosis
Respiratory alkalosis
Insulin resistance
Hematologic
Thrombocytopenia
Hemolysis
Anemia
Leukocyte dysfunction
Decreased 2,3-DPG
Renal Acute tubular necrosis
Hepatological Acute liver failure
9. Outlook
Due to the lack of large randomized trials, the current literature confirms the clinical consequences
but not the efficacy of measures used to prevent and treat RFS. A recent secondary analysis of the
EFFORT trial showed that RFS has a significant impact on mortality and readmission rate [5,6].
Therefore, prevention, detection, and early treatment of malnourished catabolic medical patients at risk
of RFS is essential [25,47,52]. As mentioned before, clinical manifestation can vary from mild to severe,
and lethal complications are possible. Therefore, an implementation of the nutritional and fluid intake
as proposed in Figure 4 seems opportune. Still, it remains unclear whether RFS is a physiological
response or a problem of adaptation to nutritional therapy [19,20]. Thus, further research is needed to
determine the optimal rate of energy and fluid increase during refeeding, as well as associated factors.
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Many other unresolved issues have not yet been clarified. Does hypoglycemia or hyperglycemia
play an important role in the clinical manifestation of RFS? Does insulin therapy influence the risk of
RFS? Is RFS caused and/or influenced by the underlying disease [87]? Is there a difference between
nutrition-induced hypophosphatemia and RFS? Are there reliable predictors of RFS [31]? For example,
increased IGF-1 combined with increased leptin levels is associated with a 30% decrease in the
phosphate level within the first 12–36 h after the start of parenteral nutrition [88]. Cytokines may also
play an important role in the pathophysiology. Many studies have shown the importance of thiamine
supplementation to avoid beriberi disease, whereas the potential action of other vitamins and trace
elements in this context is much less investigated [78,89,90].
10. Conclusions
Nutritional therapies have shown to be efficacious and efficient, despite the overall low level
of evidence. It however hides the risk of RFS in catabolic malnourished patients. RFS is a highly
challenging metabolic situation, leading to potentially life-threatening complications with fluid and
electrolyte disturbances. RFS should therefore be timely and adequately treated. As nutritional risk is
associated with the risk of RFS, awareness of both conditions must be increased among the medical
staff in daily clinical practice.
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